Last reviewed · How we verify
NCT05775224
ASH Research Collaborative Data Hub
trial in Sickle Cell Disease in 100,000 participants. Enrolling by invitation.
29 April 2099
Quick facts
| Lead sponsor | ASH Research Collaborative |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 100,000 |
| Start date | 29 April 2020 |
| Primary completion | 29 April 2099 |
| Estimated completion | 29 April 2099 |
| Sites | 1 location across United States |
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
ASH Research Collaborative
Who can join
Eligibility, any sex, with Sickle Cell Disease or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Benign and malignant hematologic diseases are relatively rare conditions within the spectrum of medical practice in any one site of care. Nonetheless, recent research in hematologic conditions from basic, translational, clinical and population perspectives offer the possibility of improving the way that these diseases are treated, and the outcomes experienced by patients. A repository that aggregates and validates this data across institutions and other practice settings is needed in order to identify variation in care, new findings, and further research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05775224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other ASH Research Collaborative trials
Trials by the same sponsor.
- NCT05831787 — COVID19 OutcomeS in Myeloma and the Impact of VaCcines · active not recruiting
- NCT05139992 — COVID-19 Vaccine Response in Sickle Cell Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05775224 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ASH Research Collaborative
- Last refreshed: 17 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing